Symbiotec Pharmalab IPO Financials, Risk Factors, Peers & Objects of Issue
An investor-focused breakdown of the Symbiotec Pharmalab IPO offer document: restated financial performance, key ratios, valuation across the price band, competitive strengths, risk factors, listed peers, objects of the issue and the business model, all drawn from the company's RHP disclosures.
Back to the Symbiotec Pharmalab IPO report → (allotment, subscription, GMP)
Symbiotec Pharmalab IPO Financial Performance (Restated)
On a restated consolidated basis, the company revenue increased by 15% and profit after tax (PAT) rose by 14% between the financial year ending with March 31, 2026, a useful one-line read on operating momentum heading into the listing.
Here is how the books have moved over the last three financial years:
31 Mar 2026 to 31 Mar 2024₹ Crore
All figures in ₹ Crore unless stated otherwise. Source: restated financials disclosed in the offer documents.
Profits have scaled from ₹100.06 Cr to ₹109.90 Cr over two years; the borrowings-to-net-worth ratio has eased to about 0.33. For investors, the trend matters more than any single year, steady compounding with contained leverage is what institutional bidders typically reward, while a late spike in borrowings deserves scrutiny against the stated objects of the issue.
Symbiotec Pharmalab IPO Key Performance Indicators (KPI)
ROE11.19%
RoCE11.56%
Return on Net Worth9.48%
NAV per share184.69
Price to Book5.35
Reading these numbers. RoE and RoCE measure how efficiently the business turns shareholder capital into profit; anything in double digits is respectable, mid-twenties plus is strong. A debt-to-equity ratio well below 1 signals a balance sheet that does not depend on lenders. NAV per share anchors the book value of your bid, while price-to-book tells you how many rupees the issue is charging for each rupee of that book, compare it with listed peers in the same sector before deciding whether the premium is justified.
Symbiotec Pharmalab IPO Valuation, Pre IPO vs Post IPO
The issue price converts into a different earnings multiple once the fresh shares hit the books. Here is the dilution-adjusted picture:
EPS (₹)17.82→ 17.39 post-IPO
P/E (x)55.44→ 56.81 post-IPO
Market Cap at offer₹6,094Cr→ ₹7,053.39 Cr post-IPO
Pre-IPO figures are computed on the pre-issue share count; post-IPO figures assume full subscription at the upper band.
Symbiotec Pharmalab IPO Competitive Strengths (as disclosed in the RHP)
Key strengths
- Rau Facility accredited with ISO 14001:2015 (Environment Management System) and ISO 45001:2018 (Occupational Health and Safety Management System).
- Quality control laboratory equipped with HPLC, UPLC, FTIR, GC, particle size analyzer, polarimeter, Karl Fischer titrators, UV spectrophotometer, TOC analyzer and microbiology lab, with SCADA and DCS real-time process control and SAP-driven material management.
- As of March 31, 2026, 450 personnel (23.50% of total permanent employees) dedicated to quality control and assurance functions.
- As of March 31, 2026, over 50 domestic customers and over 150 export customers, with average relationship tenure of >10 years with top five and >9 years with top ten customers.
- Sustainable operations: continuous manufacturing via flow chemistry for Progesterone (largest selling product), use of solar/wind renewable energy, bio-briquettes, zero liquid discharge, and Ecovadis certification across facilities.
- Intellectual property: 3 registered trademarks in classes 5,35,42; subsidiary Xenamed has 3 granted US patents, 3 granted Japan patents, 1 granted Europe patent out of filed applications.
- Global leadership in corticosteroid and steroidal hormone APIs.
- Long-standing relationships with domestic and international customers.
- Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a str
- Continuous investment in research and development, supported by strong technological capabilities among Indian
Symbiotec Pharmalab IPO Industry Snapshot
- Corticosteroid API market (Symbiotec focus products) valued at USD 421.2 million in 2025, CAGR 2.1% (2020-2025), estimated 1.6-3.0% CAGR to 2030F.
- Steroid hormones API market valued at USD 300.7 million in 2025, CAGR 1.7% (2020-2025), estimated 1.0-2.5% CAGR to 2030.
- Global GLP-1 sales increased from USD 13.5 billion in 2020 to USD 67.3 billion in 2025, grew at estimated CAGR of 36.4% (chart: 37.9%) and expected 11.5-13.5% CAGR 2025-2030.
- Global conjugated estrogen market USD 380 million in 2024 (20.6% CAGR decline 2019-2024); Symbiotec among first to introduce generic API for Premarin.
- Increased outsourcing to CDMOs with fermentation capabilities is accelerating capacity utilization and spurring advanced manufacturing investments.
- Fermentation-based large molecules pharma market size USD 82.3 billion in 2025, fastest growth at 11.0% CAGR to 2030F; high entry barriers (capital, tech, regulatory) ensure lean competitive landscape.
Symbiotec Pharmalab IPO Objects of the Issue
Excerpt does not contain the Objects of the Issue/Offer section itself; it only references 'Objects of the Offer' beginning on page 138 and shows pre-/post-Offer shareholding tables with placeholder values [●]. No stated objects or amounts available.
Disclaimer: The financial data on this page is auto-extracted from the company's offer document (RHP/DRHP) and is provided for education only. DostIpo is not a SEBI-registered investment adviser; verify all figures against the official prospectus before making any investment decision. Investments in the securities market are subject to market risks.
View the complete Symbiotec Pharmalab IPO report: allotment status, subscription, GMP & review →
Last updated: 02 Sep 2026, 22:25 IST